The technical details of two methods for measuring cell-mediated cytotoxicity against human tumor cells are described. The cytotoxic test in tissue culture microplates presents the advantage of using a low number of target and effector cells. The cytotoxic test with 51Cr allows a non subjective automatic reading. Both methods proved to be suitable to detect tumor specific antigens.
Get full access to this article
View all access options for this article.
References
1.
BachF. H., and VoynowM. K.: One-way stimulation in mixed leukocyte cultures. Science, 153: 545–547, 1966.
2.
BrunnerK. T., MauelJ., CerottiniJ. C., and ChapuisB.: Quantitative assay of the lytic action of immune lymphoid cells of 51Cr-labelled allogeneic target cells in vitro: inhibition by isoantibody and by drugs. Immunology, 14: 181–196, 1968.
3.
BubenikJ., PerlmannP., HelmsteinK., and MobergerG.: Immune response to urinary bladder tumours in man. Int. J. Cancer, 5: 39–46, 1970.
4.
EilberF. R., and MortonD. L.: Immunologic studies of human sarcomas. Proc. Amer. Ass., 11: 89, 1970.
5.
GoldsteinG., KleinG., PearsonG., and CliffordP.: Direct membrane immunofluorescence reaction of Burkitt's lymphoma cells in culture. Cancer Res., 29: 749–752, 1969.
6.
HellströmI.: A colony inhibition (CI) technique for demonstration of tumor cell destruction by lymphoid cells in vitro. Int. J. Cancer, 2: 65–68, 1967.
7.
HellströmI., HellströmK. E., PierceG. E., and YangJ. P. S.: Cellular and humoral immunity to different types of human neoplasms. Nature, 220: 1352–1354, 1968.
8.
HellströmI., and HellströmK. E.: Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas. Int. J. Cancer, 5: 195–201, 1970.
9.
HellströmI., HellströmK. E., BillA. H., PierceG. E., and YangJ. P. S.: Studies on cellular immunity to human neuroblastoma cells. Int. J. Cancer, 6: 172–188, 1970.
10.
KleinG.: Tumor antigens. Ann. Rev. Microbiol., 20: 223–252, 1966.
11.
KleinG., CliffordP., KleinE., and StjernswärdJ.: Search for tumor specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescience reaction. Proc. Nat. Acad. Sci. U.S., 55: 1628–1635, 1966.
12.
LewisM. G., IkonopisovR. L., NairnR. C., PhillipsT. M., Hamilton FairleyG., BodenhamD. C., and AlexanderP.: Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Brit. Med. J., 3: 547–552, 1969.
13.
MöllerG.: Demonstration of mouse isoantigens at the cellular level by the fluorescent antibody technique. J. exp. Med., 114: 415–434, 1961.
14.
NagelG. A., St.-ArneaultG., HollandJ. F., and KirkpatrickR.: Cell-mediated immunity against malignant melanoma in monozygous twins. Cancer Res., 30: 1828–1832, 1970.
15.
OldL. J., and BoyseE. A.: Antigens of tumors and leukemias induced by viruses. Fed. Proc., 24: 1009–1017, 1965.
16.
PrehnR. T.: Cancer antigens in tumors induced by chemicals. Fed. Proc., 24: 1018–1022, 1965.
17.
StjernswärdJ., JohanssonB., SvedmyrE., and SundbladR.: Indication of tumor-specific cellbound immunological reactivity and depressed general reactivity in a pair of twins. Clin. exp. Immunol., 6: 429–434, 1970.
18.
TakasugiM., and KleinE.: A microassay for cell-mediated immunity. Transplantation, 9: 219–227, 1970.
